LGND

Ligand Pharmaceuticals Incorporated · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-27

Figures on this page computed 2026-11-08 12:48 UTC

Last close

316.13USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-27

47.5xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-27
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
The filing itself
46.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
18.2%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.13 against 0.37 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Against its rival

lens 4 of 9

Measure by measure

behind on 2 of 2

Profit on each unit of sales46.4%52.6%Behind
Higher is better here.
Return on the capital it usesn/an/an/a
Higher is better here.
Sales growth over five years10.4%n/an/a
Higher is better here.
Debt against equityn/an/an/a
Lower is better here.
Gross marginn/an/an/a
Higher is better here.
Price against earnings47.6x42.5xBehind
Lower is better here.

The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.

Against Krystal Biotech, Inc., LGND is behind on 2 of 2 measures.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-27

Profit on each unit of sales46.4%
Source
filed
Statement
income
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
The filing itself
Return on the capital it usesn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
The filing itself
Sales growth over five years10.4%
Source
filed
Statement
income
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
The filing itself
Debt against equityn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
The filing itself
Gross marginn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
The filing itself
Price against earnings47.5x
Source
filed
Statement
income
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
The filing itself